GENERATION OF PANCREATIC ENDOCRINE CELLS FROM PRIMARY DUCT CELL CULTURES AND METHODS OF USE FOR TREATMENT OF DIABETES

• US 20080260700A1
• Filed: 02/26/2008
• Published: 10/23/2008
• Est. Priority Date: 08/26/2005
• Status: Abandoned Application

• Current Assignee: Trustees Of Columbia University In The City Of New York (Columbia University)
• Original Assignee: Trustees Of Columbia University In The City Of New York (Columbia University)
• Inventors: Kitamura, Tadahiro, ACCILI, Domenico
• Application Number:
  US12/037,401
• Publication Number:
  US 20080260700A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2501/117 Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

The invention is directed to spontaneously immortalized pancreatic duct cells and methods for generating pancreatic endocrine cells from spontaneously immortalized pancreatic duct cells that express the transcription factors Pdx1 and FoxO1. The invention also provides for methods for treating beta cell failure, the method comprising administering to a subject an effective amount of spontaneously immortalized pancreatic duct cells expressing a mutated version FoxO1.

Claims

1. An immortalized pancreatic duct cell derived from a primary adult pancreatic duct epithelial cell culture, wherein the immortalized cell expresses Pdx1 and FoxO1.

2. The cell of claim 1, wherein the cell expresses pancreatic duct cell markers.

3. The cell of claim 2, wherein the pancreatic duct cell markers comprise cytokeratin 16 and carbonic anhydrase II.

4. The cell of claim 1, wherein the cell does not express endocrine pancreatic markers.

5. The cell of claim 4, wherein the endocrine pancreatic markers comprise insulin, glucagon, somatostatin and pancreatic polypeptide.

6. The cell of claim 1, wherein the cell does not express exocrine pancreatic markers.

7. The cell of claim 6, wherein the exocrine pancreatic markers comprise amylase, trypsin and elastase.

8. The cell of claim 1, wherein the cell is a human cell.

9. An immortalized pancreatic duct cell derived from a primary adult pancreatic duct epithelial cell, wherein the cell expresses mutated FoxO1.

10. The cell of claim 9, wherein the cells express endocrine pancreatic markers.

11. The cell of claim 10, wherein the endocrine pancreatic markers comprise Isl1, Nkx6.1, Nkx2.2, NeurodD1, glucagon and pancreatic polypeptide.

12. The cell of claim 9, wherein the mutated version of FoxO1 contains a loss-of-function mutation.

13. A pancreatic duct cell line designated 24-1 Duct having ATCC Accession No. PTA-6968.

14. A method for treating beta cell failure, the method comprising administering to a subject spontaneously immortalized pancreatic ductal cell line expressing mutated FoxO1.

15. The method of claim 14, wherein the administering comprises infusion, injection, incapsulation, or any combination thereof.

16. The method of claim 14, wherein the administering comprises transplanting a sponge matrix comprising immortalized pancreatic ductal cells expressing mutated FoxO1 or Spontaneously Immortalized Pancreatic Duct Cells (SIPDC)-derived hormone-producing cells.

17. A method for obtaining a pancreatic duct cell line, the method comprising:

(a) culturing pancreatic duct cells collected from a subject in medium comprising about 10% serum and 5.5 mM glucose for about a week;

(b) culturing the cells in a medium comprising (i) about 8 mM glucose;

(ii) about 1 g/L ITS (about 5 mg/l insulin and about 5 mg/l transferrin and about 5 mg/l selectin), (iii) about 2 g/l albumin, (iv) about 10 mM nicotinamide, and (v) about 10 mg/ml keratinocyte growth factor, for about at least another week until the culture comprises nearly all duct cells;

(c) culturing the duct cells with the medium of step (b) further comprising about 10% serum and about 5.5 mM glucose;

(d) passaging the cells of step (c) until the cells'"'"' doubling time reach about 24 hours; and

(e) cloning a single cell from the cells of step (d) so as to obtain a pancreatic duct cell line.